Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,055.96
(
-1.27%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 150407

Thursday, 10/11/2012 7:55:30 AM

Thursday, October 11, 2012 7:55:30 AM

Post# of 257579

Assuming thrice-weekly Copaxone entry in early 2014…

That may be optimistic. Before reviewing the NDA, the FDA may want to see the results of GALA’s open-label safety extension, which is slated to run until May 2014 (http://clinicaltrials.gov/ct2/show/NCT01067521 ). If so, market entry will likely be delayed until mid 2015.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today